BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 22361634)

  • 21. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.
    Zhou W; Jirström K; Johansson C; Amini RM; Blomqvist C; Agbaje O; Wärnberg F
    BMC Cancer; 2010 Nov; 10():653. PubMed ID: 21118480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
    BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of Residual Tumor in Breast-Conserving Therapy.
    Rath MG; Uhlmann L; Heil J; Domschke C; Roth Z; Sinn HP; Marme F; Scharf A; Schneeweiss A; Kieser M; Sohn C; Rom J
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S451-8. PubMed ID: 26224405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ.
    Toss MS; Miligy IM; Haj-Ahmad R; Gorringe KL; AlKawaz A; Mittal K; Ellis IO; Green AR; Rakha EA
    Histopathology; 2019 Jun; 74(7):1025-1035. PubMed ID: 30725481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinic-Pathological Features of Breast Ductal Carcinoma
    Zheng J; Zhou T; Li F; Shi J; Zhang L
    Cancer Invest; 2020 Feb; 38(2):113-121. PubMed ID: 31939679
    [No Abstract]   [Full Text] [Related]  

  • 26. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
    Solin LJ; Gray R; Baehner FL; Butler SM; Hughes LL; Yoshizawa C; Cherbavaz DB; Shak S; Page DL; Sledge GW; Davidson NE; Ingle JN; Perez EA; Wood WC; Sparano JA; Badve S
    J Natl Cancer Inst; 2013 May; 105(10):701-10. PubMed ID: 23641039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term Survival Comparison of Repeated Breast-conserving Surgery Versus Mastectomy for Patients with DCIS with Ipsilateral Breast Tumor Recurrence: A Real-world Longitudinal Study.
    Li Q; Wang K; Yang L; Wu Q; Zhu W; Li Z; Shi Y; Zhang X; Li H
    Clin Breast Cancer; 2021 Aug; 21(4):360-372. PubMed ID: 33846099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy.
    Kerlikowske K; Molinaro A; Cha I; Ljung BM; Ernster VL; Stewart K; Chew K; Moore DH; Waldman F
    J Natl Cancer Inst; 2003 Nov; 95(22):1692-702. PubMed ID: 14625260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
    de Roos MA; van der Vegt B; Peterse JL; Patriarca C; de Vries J; de Bock GH; Wesseling J
    Histopathology; 2007 Aug; 51(2):227-38. PubMed ID: 17650217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.
    Solin LJ; Gray R; Hughes LL; Wood WC; Lowen MA; Badve SS; Baehner FL; Ingle JN; Perez EA; Recht A; Sparano JA; Davidson NE
    J Clin Oncol; 2015 Nov; 33(33):3938-44. PubMed ID: 26371148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Underestimation of invasive lesions in patients with ductal carcinoma in situ of the breast diagnosed by ultrasound-guided biopsy: a comparison between patients with and without HER2/neu overexpression.
    Chang WC; Hsu HH; Yu JC; Ko KH; Peng YJ; Tung HJ; Chang TH; Hsu GC
    Eur J Radiol; 2014 Jun; 83(6):935-941. PubMed ID: 24666513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Higher density of stromal M2 macrophages in breast ductal carcinoma in situ predicts recurrence.
    Chen XY; Thike AA; Md Nasir ND; Koh VCY; Bay BH; Tan PH
    Virchows Arch; 2020 Jun; 476(6):825-833. PubMed ID: 31897820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients.
    Zhao X; Mirza S; Alshareeda A; Zhang Y; Gurumurthy CB; Bele A; Kim JH; Mohibi S; Goswami M; Lele SM; West W; Qiu F; Ellis IO; Rakha EA; Green AR; Band H; Band V
    Breast Cancer Res Treat; 2012 Jul; 134(1):171-80. PubMed ID: 22270930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ductal carcinoma-in-situ: long-term results of breast-conserving therapy.
    Mirza NQ; Vlastos G; Meric F; Sahin AA; Singletary SE; Newman LA; Kuerer HM; Ames FC; Ross MI; Feig BW; Pollock RE; Buchholz TA; McNeese MD; Strom EA; Hortobagyi GN; Hunt KK
    Ann Surg Oncol; 2000 Oct; 7(9):656-64. PubMed ID: 11034242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy.
    Rakovitch E; Pignol JP; Hanna W; Narod S; Spayne J; Nofech-Mozes S; Chartier C; Paszat L
    J Clin Oncol; 2007 Dec; 25(35):5591-6. PubMed ID: 17984188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone.
    Rakovitch E; Nofech-Mozes S; Hanna W; Baehner FL; Saskin R; Butler SM; Tuck A; Sengupta S; Elavathil L; Jani PA; Bonin M; Chang MC; Robertson SJ; Slodkowska E; Fong C; Anderson JM; Jamshidian F; Miller DP; Cherbavaz DB; Shak S; Paszat L
    Breast Cancer Res Treat; 2015 Jul; 152(2):389-98. PubMed ID: 26119102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation.
    Solin LJ; McCormick B; Recht A; Haffty BG; Taylor ME; Kuske RR; Bornstein BA; McNeese M; Schultz DJ; Fowble BL; Barrett W; Yeh IT; Kurtz JM; Amalric R; Fourquet A
    Cancer J Sci Am; 1996; 2(3):158-65. PubMed ID: 9166516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
    Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.